title: Management of Hypertension Using Olmesartan Alone or in Combination.
abstract: Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hypertension. Concerning the high morbidity rate, setting up an updated standard for hypertensive patients becomes indispensable. According to the widely accepted standard treatments for hypertension, these four basic principles should be taken into account: low dosage; medication should provide long term-control; combination therapies are becoming common; personalized treatments are a newer approach. In most patients with hypertension, adequate control of BP can be achieved with combined therapy. Therefore, antihypertensive agents with complementary mechanisms are now recommended. In this review, we focus on the pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan medoxomil, either alone or in combination with other antihypertensive medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients.
authors.affiliation: Department of Cardiology, Shanghai Tenth Hospital of Tongji University, Shanghai, 200072, China.|Tongji University Cancer Institute, Tongji University School of Medicine, Shanghai, 200092, China.|Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, 02114, USA.
authors.forename: Xiaoshen
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Cardiology, Shanghai Tenth Hospital of Tongji University, Shanghai, 200072, China.
authors.forename: Han
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Internal Medicine, Cangzhou Central Hospital, Cangzhou, China.
authors.forename: Yuxia
authors.initials: Y
authors.lastname: Ma
authors.affiliation: Department of Cardiology, Shanghai Tenth Hospital of Tongji University, Shanghai, 200072, China.
authors.forename: Wenliang
authors.initials: W
authors.lastname: Che
authors.affiliation: Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, 02114, USA. hamblin@helix.mgh.harvard.edu.|Department of Dermatology, Harvard Medical School, Boston, MA, 02115, USA. hamblin@helix.mgh.harvard.edu.|Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, 02139, USA. hamblin@helix.mgh.harvard.edu.
authors.forename: Michael R
authors.identifier: http://orcid.org/0000-0001-6431-4605
authors.initials: MR
authors.lastname: Hamblin
keywords: Angiotensin II receptor blockers; Blood pressure control; Combination drug treatment; Hypertension; Olmesartan medoxomil